PPCB logo

PROPANC BIOPHARMA INC

PPCBNASDAQ
🏆 #5403 by market capUS Equity
$527.74▼ $23.12 (−4.38%)
Simulated price
🔔
Track PPCB
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.4%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
48
Weak
No chart data available for PPCB.

Trading Snapshot

Day Range
$525.85 – $534.77
52-Week Range
$0.52 – $52.50
Volume
$1.90B
Avg Volume
$2.24B
Shares Outstanding
2.3M
Next Earnings
Oct 29, 2026

Fundamentals Snapshot

Annual Revenue
$199,227
Last Q Revenue
$55,020
P/E Ratio
-0.0
P/S Ratio
0.0x
EPS (TTM)
$-5.70
Dividend Yield
0.00%
Dilution (1yr)
+100000.1%

Why Investors Own PPCB

  • ✓High-growth profile — revenue up +2.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 75% gross margin and 13% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PPCB logo

PROPANC BIOPHARMA INC

PPCB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$57M▲ +3629.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$405K▼ −56.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
534K▲ +100000.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$88K▲ +$1M YoY
StockOtter · stockotter.space

About PROPANC BIOPHARMA INC

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Price Target

ⓘ
Average Target
$520.63
▼ −1.3% Downside
High Target$605.86
Low Target$441.42
Based on 38 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

PROPANC BIOPHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift PPCB price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

PROPANC BIOPHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.